Development of novel therapies for Huntington's disease:hope and challenge

作     者：Zheng-hong QIN~(2,3,5),Jin WANG~4,Zhen-lun GU~2~2Department of Pharmacology,Soochow University School of Medicine,Suzhou 215007,China ~3Laboratory of Cellular Neurobiology,Massachusetts General Hospital and Harvard Medical School,Charlestown,MA 02129,USA ~4Molecular Neurogenetics Unit,Center forHuman Genetics Research,Massachusetts General Hospital and Harvard Medical School,Charlestown,MA 02129,USA 

作者机构：Department of Pharmacology Soochow University School of Medicine Suzhou China Laboratory of Cellular Neurobiology Massachusetts General Hospital and Harvard Medical School Charlestown USA Molecular Neurogenetics Unit Center for Human Genetics Research Massachusetts General Hospital and Harvard Medical School Charlestown USA 

出 版 物：《Acta Pharmacologica Sinica》 (中国药理学报(英文版))

年 卷 期：2005年第26卷第2期

页      面：129-142页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China(№ 30370506) 

主　　题：Huntington disease huntingtin aggregates caspases nerve growth factors cell transplantation coenzyme Q10 

摘      要：Huntington s disease(HD)is an autosomal dominant neurological *** is afatal neurological disorder affecting 5-10 out of 10000 *** there areintensive research efforts focusing on uncovering molecular mechanisms of thepathogenesis of HD,a number of studies have begun to look for effective thera-pies for *** is a large body of encouraging news on novel *** present paper reviews drugs used for symptomatic treatmentof HD and experimental therapies targeting HD molecular pathology.